ArticleBMC medical research methodology2025
A randomized Bayesian phase I-II dose optimization design for combination cancer therapies with progression-free survival end point.
Yingjie Qiu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.